Gliomas Clinical Trials

A listing of Gliomas medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 114 clinical trials
Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas

hyperpolarized metabolic MRI to diagnose intermediate to patients with infiltrating gliomas and examine the added utility of metabolic MRI over standard MRI imaging The FDA is allowing the use of

  • 0 views
  • 04 Mar, 2021
  • 1 location
Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma

This phase I trial studies the side effects and best dose of panobinostat in treating younger patients with diffuse intrinsic pontine glioma (DIPG). Panobinostat may stop the growth of tumor

potassium
anticonvulsants
panobinostat
erythropoietin
tumor progression
  • 27 views
  • 26 Mar, 2021
  • 10 locations
CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas

nanoparticle formulation) and Gadolinium that can be given safely in children with newly diagnosed diffuse midline gliomas. All patients enrolled in the study will receive infusion of MTX110 and Gadolinium

neutrophil count
seizures
epilepsy
anticonvulsants
platelet count
  • 1 views
  • 28 Jan, 2021
A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

This is a pilot, randomized, two arm neoadjuvant vaccine study in human leukocyte antigen-A2 positive (HLA-A2+) adults with World Health Organization (WHO) grade II glioma, for which surgical

oligoastrocytoma
temodar
hiltonol
low grade glioma
corticosteroids
  • 25 views
  • 09 Jun, 2021
  • 1 location
Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma

This phase I trial studies the side effects and best dose of memory-enriched T cells in treating patients with grade II-IV glioma that has come back (recurrent) or does not respond to treatment

cytotoxic chemotherapy
immunohistochemistry
dexamethasone
erbb2
bevacizumab
  • 100 views
  • 26 Jan, 2021
  • 3 locations
Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas

The purpose of this study is to determine the maximum tolerated dose (MTD) and select optimal biological doses (OBD) of the study drug NT-I7 in High Grade Glioma patients with severe lymphopenia

aptt
gliadel
corticosteroids
brain tumor
biologic agent
  • 0 views
  • 27 Apr, 2021
  • 12 locations
ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

this research study is evaluating the highest dose of ASTX727 that can be administered safely to recurrent/progressive non-enhancing IDH mutant gliomas patients.

  • 3 views
  • 25 Jan, 2021
Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)

Background Currently, no standard treatment exists for patients with recurrent glioblastoma multiforme (rGBM) and used 2nd line treatments have low (up to max. 20%) response rates and very modest response duration (months). The median overall survival for GBM patients is 12-14 months from the time of diagnosis; therefore the development …

recurrent glioblastoma
procarbazine
recurrent disease
cytotoxic chemotherapy
cis-retinoic acid
  • 147 views
  • 25 Jan, 2021
  • 1 location
Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma

The purpose of this study is to test how well the drug works, safety and tolerability of an investigational drug called Ruxolitinib in gliomas and glioblastomas, when combined with standard

methylated
anaplastic astrocytoma
oligodendroglioma
astrocytoma, anaplastic
anaplastic oligodendroglioma
  • 31 views
  • 12 Jun, 2021
  • 2 locations
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

receptor (CAR) and EGFRt. CAR T cells are delivered via an indwelling catheter into the tumor resection cavity or ventricular system in children and young adults with diffuse intrinsic pontine glioma (DIPG

tumor resection
mg++
tumour resection
apheresis
diffuse intrinsic pontine glioma
  • 8 views
  • 22 Mar, 2021
  • 1 location